Course Description
Activity Dates: 04/04/2027 - 1/29/2028
The Clinical Application Series is an application-based continuing pharmacy education (CPE) activity designed to advance the knowledge and improve competency of participants through the delivery of evidence-based presentations. The interactive presentations are delivered live over two days at the AAPP Annual Meeting and provide knowledge and tools to improve the comprehensive care of patients with mental health disorders.
- Includes online access to the recorded speakers' audio presentations synchronized with their slide presentations (presented live at AAPP 2027 on April 5 and April 6 in Louisville, KY).
- Provides pharmacists, 10 hours of ACPE credit and 10 hours of BCPP recertification credit achieved by successfully completing the online AAPP recertification assessment. BCPP recertification credit is earned and reported within the year the assessment is successfully completed (2027 or 2028).
- Includes access to the AAPP learning management system with assessment submission due on or before January 29, 2028. Assessment extensions will not be granted after assessment deadlines. In cases of personal or family illness that prevents completion of an assessment, AAPP will transfer your product purchase to a comparable BCPP Recertification course after a letter documenting the unique circumstances is received by the AAPP office.
Consider making these presentations part of your BPS Continuing Professional Development plan! Please refer to the BPS Psychiatric Pharmacy Content Outline to see how this activity may align.
Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful assessment completion.
The Clinical Application Series (CAS), a BCPP recertification product, is offered live at AAPP's Annual Meeting. AAPP members who register for the Annual Meeting (full registration only) get 50% off CAS! Members must be registered for the Annual Meeting before registering for CAS to receive the 50% discount.
Learning Objectives
When Panic Persists: Navigating Difficult to Treat Panic Disorder
1. Recommend a pharmacologic or nonpharmacologic next step for a patient with persistent panic disorder symptoms after first-line treatment.
2. Evaluate the evidence and limitations of emerging strategies for difficult-to-treat panic disorder.
3. Select appropriate measures of treatment response and safety monitoring for a patient receiving treatment for difficult-to-treat panic disorder.
Medication Strategies for Behavioral and Psychological Symptoms of Dementia
1. Describe clinical features of behavioral and psychological symptoms of dementia (BPSD) associated with neurocognitive disorders.
2. Analyze safety and efficacy of pharmacotherapy in BPSD.
3. Choose an individualized treatment plan for patients with BPSD.
Mastering Mood Stabilizers: Navigating Interactions & Adverse Effects
1. Identify clinically significant drug interactions or adverse events that can occur with mood stabilizers.
2. Outline a monitoring plan for mood stabilizers to mitigate adverse effects.
3. Devise patient-centered education on mood stabilizers.
Neuropsychiatric comorbidities of multiple sclerosis
1. Identify common psychiatric symptoms in patients with multiple sclerosis.
2. Analyze the safety and efficacy of treatment options for comorbid psychiatric symptoms in multiple sclerosis.
3. Select a treatment regimen for an individual with co-occurring psychiatric symptoms and multiple sclerosis.
Psychosis in the Context of Substance Use: Primary Diagnosis or Substance Effect?
1. Identify substances that cause substance-induced psychosis.
2. Choose appropriate treatment strategies for managing psychotic symptoms in the context of substance use.
3. Assess the role of a clinical pharmacist in managing patients with psychosis from substance use.
Managing Psychiatric Symptoms in Neurogenetic Syndromes
1. Identify psychiatric symptoms associated with neurogenetic disorders.
2. Analyze the risks and benefits of medications in the management of psychiatric symptoms due to a neurogenetic disorder.
3. Devise a treatment plan to manage psychiatric symptoms for a patient with a neurogenetic disorder.
Antiseizure Medications in Neuropsychiatric Practice: Identifying, Preventing, and Managing Adverse Effects
1. Identify common and neuropsychiatric adverse effects of antiseizure medications.
2. Choose strategies to prevent adverse effects of antiseizure medications.
3. Develop a treatment plan to manage adverse effects of antiseizure medications.
Legal and Ethical Decision-Making in Involuntary Commitment
1. Describe legal considerations for involuntary treatment.
2. Apply ethical principles in treatment planning for individuals who are under involuntary commitment.
3. Choose pharmacologic treatment for those under involuntary commitment.
Target Audience
BCPPs desiring an evidence-based, in-depth review of contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who are auditory and visual learners and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.
Course Requirements
To satisfactorily complete the recertification programming and receive BCPP Recertification and ACPE credit, candidates must meet the following requirements:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Abide by a confidentiality and honesty statement requiring individual completion of the course.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete an activity evaluation form.
- Wait for an official review of exam questions within 4 weeks following the closing date.
- Receive a passing grade (TBD).
- Partial credit is not provided; your exam score must meet or exceed the cut-off score in order to receive the ACPE and BCP Recertification credit.
- Learners who do not achieve a passing score on a post-activity assessment may appeal assessment questions and/or take a remediation assessment. View AAPP's Post-Activity Assessment Appeal and Remediation Policy.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Continuing Education Credit and Disclosures
Activity Dates: 04/04/2027 - 1/29/2028
ACPE Contact Hours: 10
ACPE Numbers: TBA
 | The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
View Editorial Board Disclosures of Interest
Cynthia Kirkwood, PharmD, BCPP, FASHP, FAAPP
Chair
Professor Emeritus
Virginia Commonwealth University School of Pharmacy
Barboursville, VA
Stock Shareholder: Pfizer
Marissa Cullen, PharmD, BCPP
Senior Editor
Clinical Pharmacist
UPMC Western Psychiatric Hospital
Pittsburgh, PA
No Relevant Financial Relationships to Disclose
Archana Jhawar, PharmD, BCPP
Senior Editor
Clinical Pharmacist
University of Illinois at Chicago College of Pharmacy
Chicago, IL
No Relevant Financial Relationships to Disclose
Beth DeJongh, PharmD, BCPS, BCPP
Director of Continuing Professional Development
American Association of Psychiatric Pharmacists
Lincoln, NE
No Relevant Financial Relationships to Disclose
Sarah Benner, PharmD, BCPS, BCPP
Psychiatric Clinical Pharmacist
TidalHealth
Salisbury, MD
No Relevant Financial Relationships to Disclose
Bridget Bradley, PharmD, BCPP
Clinical Pharmacy Specialist - Mental Health
Kaiser Permanente Northwest
Beaverton, OR
No Relevant Financial Relationships to Disclose
Kayla Johnson, PharmD, BCPP, BCPS
Clinical Pharmacist Specialist
Vanderbilt University Medical Center
Thompsons Station, TN
Consultant: Teva Pharmaceuticals
Emily Leppien, PharmD, BCPS, BCPP
Clinical Associate Professor
Binghamton University
Binghamton, NY
No Relevant Financial Relationships to Disclose
Michael McGuire, PharmD, BCPP
Professor of Pharmacy Practice
Belmont University College of Pharmacy and Health Sciences
Nashville, TN
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Alkermes, Bristol-Myers Squibb
Kristen Nagy, PharmD, BCPP, BCPS
Clinical Pharmacy Coordinator-Psychiatry
Atrium Health Behavioral Health Center-Charlotte
Charlotte, NC
No Relevant Financial Relationships to Disclose
Katie Smithwick, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist, Psychiatry
VCU Health
Richmond, VA
No Relevant Financial Relationships to Disclose
Andreea Temelie, PharmD, BCPP
Clinical Pharmacist - Child/Adolescent Psychiatry
UPMC Western Psychiatric Hospital
Pittsburgh, PA
No Relevant Financial Relationships to Disclose
All relevant relationships have been mitigated.
View AAPP's Disclaimer and Disclosure Declarations
AAPP Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unlabeled Use Disclosure: Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. The faculty, planners, and American Association of Psychiatric Pharmacists do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
View AAPP's Copyright Statement, Terms of Use, and Policies
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View AAPP's Privacy Policy. AAPP's Terms of Use and other policies on education programs, resources, toolkits, and other web based content/offerings are available here.
View AAPP's Fair Balance and Integrity Statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.